Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. · 2017
Read Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. by Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5493145.txt.
Introduction
Farshidfar and co-authors report a genomic study in Cell Reports on cholangiocarcinoma. This cancer grows in the bile ducts and carries a poor outlook. Treatment options are few, and tumor biology varies a lot. The Cancer Genome Atlas team profiled a set of mostly intrahepatic cases. They joined mutation, gene activity, copy number, and methylation data.
One subtype stood out, rich in IDH gene mutations. That group showed high mitochondrial gene activity and more mitochondrial DNA copies. A chromatin gene, ARID1A, was silenced by methylation in this group. The authors propose a molecular sorting scheme for these tumors. Such sorting may guide future targeted treatment.
Catalog record
| CREATOR | Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles By Farshad Farshidfar, Siyuan Zheng, Marie-Claude Gingras, Yulia Newton, Juliann Shih, A. Gordon Robertson, Toshinori Hinoue, Katherine A. Hoadley, Ewan A. Gibb, Jason Roszik, Kyle R. Covington, Chia-Chin Wu Published in: Cell reports DOI: 10.1016/j.celrep.2017.02.033 ABSTRACT Summary Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance. INTRODUCTION Cholangiocarcinomas (CCAs) are a group of malignancies of the biliary epithelium (cholangiocytes), comprising invasive carcinomas that arise in the intrahepatic, perihilar, and extrahepatic biliary tree (Razumilava and Gores, 2014). Most patients with CCA present with advanced disease and have a median survival of less than 1 year despite treatment with current standard chemotherapy (Valle et al., 2010). Even patients who undergo apparently curative resection have poor outcomes due to a high rate of tumor recurrence (Razumilava and Gores, 2014). Although intrahepatic, perihilar, and extrahepatic CCAs share morphologic features and have traditionally been aggregated in clinical trials, it is now apparent that there are important differences in tumor biology and genetics among tumors from different anatomic sites (Chan-On et al., 2013; Churi et al., 2014). Further elucidation of molecular alterations in these heterogeneous tumors and discovery of meaningful subtypes within each anatomic group are important steps toward developing more rational, specific, and effective treatments (Kelley and Bardeesy, 2015). Cholangiocarcinoma is the second most common type of primary liver tumor, and its incidence has been rising in the United States, from 0.44 per 100,000 in 1973 to 1.18 in 2012 (Saha et al., 2016). The actual incidence of the disease is likely much higher, as recent gene expression studies suggest that “carcinomas-of-unknown primary” identified in the liver most commonly originate from biliary epithelium (Varadhachary and Raber, 2014). Worldwide, the highest incidence of CCA is found in northeastern Thailand, where parasitic infection by liver flukes (Clonorchis sinensis and Opistorchis viverrini) leads to infestation of the biliary tree (Razumilava and Gores, 2014). In regions without liver fluke infestation, CCA disease etiologies include: primary sclerosing cholangitis, hepatitis B or C virus (HBV/HCV) infection, biliary stone disease, congenital biliary malformations, cirrhosis, and exposure to aromatic toxins (Razumilava and Gores, 2014). Lifestyle-related factors such as smoking, alcohol consumption, and diabetes also contribute to the risk of intrahepatic CCA (iCCA) (Palmer and Patel, 2012). Given the diversity of risk factors influencing the mutational spectrum and the distinct cellular origins of the CCA subtypes, there is still an incomplete appreciation of the mechanisms of biliary carcinogenesis. Prior studies indicate that iCCAs are unusual among epithelial cancers in having a relatively high rate of missense mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes (Borger et al., 2012; Chan-On et al., 2013; Jiao et al., 2013; Kipp et al., 2012; Ross et al., 2014; Wang et al., 2013), which encode metabolic enzymes that interconvert isocitrate and alpha-ketoglutarate in central carbon metabolism. These mutations, which are also common in acute myeloid leukemia, low-grade glioma and glioblastoma, and chondrosarcoma, occur at defined hotspots and result in neomorphic enzyme activity, leading to production of high levels of the metabolite (R)-2-hydroxyglutarate (2HG) (Losman and Kaelin, 2013). 2HG does not participate in normal metabolic processes but instead interferes with the function of enzymes that utilize alpha-ketoglutarate as a co-enzyme, including histone and DNA demethylases, and inhibits the mitochondrial electron transport chain (Fu et al., 2015; Parker and Metallo, 2015). Additional recurrent mutations and fusions have been reported in CCAs involving the fibroblast growth factor receptor 2 (FGFR2) gene, as well as in KRAS, BRAF, TP53, and in genes encoding chromatin-modifying enzymes (Borad et al., 2014; Churi et al., 2014; Jiao et al., 2013; Nakamura et al., 2015; Ross et al., 2014; Sia et al., 2015). Given this complexity, it is imperative to generate a more integrative model of the molecular alterations in iCCA to better define the oncogenic circuitry and to derive a classification system that groups tumors into biologically meaningful subtypes that can be used to guide therapy. In this study, we describe molecular features of 38 liver fluke-negative CCAs—predominantly intrahepatic and hepatitis negative—that stratify the disease into distinct groups. Most notably, we identify a class of CCAs with distinct transcriptomic, copy number, and methylation profiles that are highly enriched for IDH mutant samples. We also identify pathways and methylation patterns that we validate in external datasets and which could help lead to the development of more effective treatments. Finally, cross-platform comparisons of CCA with pancreatic cancer and hepatocellular carcinoma (HCC) further emphasize the presence of distinct tumor subsets. RESULTS Samples We analyzed 38 CCA samples that were predominantly from North America (89%), intrahepatic (84%), fluke-negative (100%), and HBV/HCV-negative (97%, as assessed by combined DNA and RNA sequencing, which also revealed no HBV integration sites), and had no prior exposure to chemotherapy or radiation (Tables 1 and S1). This relative overall sample uniformity minimizes known and potential sources of molecular heterogeneity in our sample set. The TCGA analysis pipeline used in this study consists of the following platforms: wholeexome sequencing; Affymetrix SNP 6.0 copy number array; RNA sequencing (RNA-seq), including microRNA (miRNA) and long noncoding RNA (IncRNA); DNA methylation; and reverse-phase protein array (RPPA) utilizing 192 antibodies. These datasets are annotated with relevant clinical information and careful histopathologic review by several experienced hepatobiliary pathologists (Table S1). Gene-Level Mutations, Fusions, and Copy Number Alterations We first annotated alterations to specific genes. Whole-exome sequencing identified 2,831 somatic mutations, of which 1,869 (66%) were non-silent coding mutations. Targeted-capture, deep sequencing validation of 43 selected genes confirmed 77 mutations and newly identified nine (see Supplemental Experimental Procedures and Table S2). The median mutation rate was 1.38 per megabase, with a median mutation count of 49 (Figure 1A; Table S1). Compared to other cancers assessed by TCGA (Lawrence et al., 2013), this CCA mutation rate is intermediate, and comparable to that of pancreatic ductal adenocarcinoma (PDAC). Consistent with previous studies, we identified inactivating mutations in the tumor suppressor genes ARID1A, ARID1B, BAP1, PBRM1, TP53, STK11, and PTEN, and hotspot gain-of-function mutations in the oncogenes IDH1, IDH2, KRAS, BRAF, and PIK3CA (Figures 1A and S1A; Tables S1 and S3). Also consistent with prior reports, the IDH mutant alleles described in our cohort (IDH1R132C and IDH2R172K/S) are distinct from those found in glioma and acute myeloid leukemia (enriched for IDH1R132H and IDH2R140Q) (Cancer Genome Atlas Research Network, 2013; Brat et al., 2015). In two tumors, we identified a recurrent P216L mutation in the regulatory domain of ARAF adjacent to the